NBD-14270 |
| Katalog-Nr.GC65903 |
NBD-14270, ein Pyridin-Analogon, ist ein potenter HIV-1-Entry-Antagonist mit einem IC50 von 180 nM gegen 50 HIV-1-Env-pseudotypisierte Viren. NBD-14270 bindet an HIV-1 gp120 und zeigt starke antivirale AktivitÄt. NBD-14270 zeigt eine geringe ZytotoxizitÄt (CC50>100 μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2411819-82-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC50>100 μM)[1][2].
NBD-14270 has anti-HIV-1 activity (IC50=0.16 μM ) and Cytotoxicity (CC50=109.3 μM) in single-cycle (TZM-bl Cells) assay[1].
NBD-14270 does not induce toxicity in the U87-CD4-CXCR4 cell line at the doses used for this assay[1].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *